Rare cancers, though individually rare by definition, represent almost a quarter of the total adult cancer burden when grouped together. Few traditional trials exist for these patients, many physicians know little about such tumors, and approved therapies are limited or nonexistent. The 2019 Rare Cancers Special Report features interviews with those who are leading the charge in affecting change on the rare cancer front, as well as reports on NCI-MATCH and the DART trial, and other resources for physicians and patients.
Rare cancers, though individually rare by definition, represent almost a quarter of the total adult cancer burden when grouped together. Few traditional trials exist for these patients, many physicians know little about such tumors, and approved therapies are limited or nonexistent. The 2019 Rare Cancers Special Report features interviews with those who are leading the charge in affecting change on the rare cancer front, as well as reports on NCI-MATCH and the DART trial, and other resources for physicians and patients.
Rare cancers, though individually rare by definition, represent almost a quarter of the total adult cancer burden when grouped together. Few traditional trials exist for these patients, many physicians know little about such tumors, and approved therapies are limited or nonexistent. The 2019 Rare Cancers Special Report features interviews with those who are leading the charge in affecting change on the rare cancer front, as well as reports on NCI-MATCH and the DART trial, and other resources for physicians and patients.
